

Bibliometric and Visual Analysis of Alzheimer's Disease and Herpes Simplex Virus Type 1 Infection Between 1990 and 2024

Hongling Ren¹, Ruiyao Song¹, Hairong Wang¹, Qingyan Zeng¹, Yu Fu¹, Yunchu Guo¹, Ying Xie², Yusong Ge¹

¹The Department of Neurology, the second Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, 116023, People's Republic of China; ²The Department of Infection Control and Prevention, the second Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, 116023, People's Republic of China

Correspondence: Yusong Ge; Ying Xie, The second Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian City, Liaoning Province, 116023, People's Republic of China, Tel +86-17709873200; +86-17709877781, Email geyusongmed@dmu.edu.cn; 936135710@qq.com

Background: Recently, some studies suggested that Herpes simplex virus type 1 (HSV-1) infection is an important environmental factor for Alzheimer's disease (AD). The literature on research about HSV-1 infection and AD is emerging. This study used the bibliometric method to investigate the relationship between HSV-1 infection and AD.

Methods: We searched the Web of Science Core Collection for relevant literature on AD and HSV-1 from 1990 to 2024. Bibliometric and visualization analyses were performed using VOSviewer and CiteSpace.

Results: From 1990 to 2024, the number of publications showed an increasing trend. The United States made the largest contributions in productivity. The University of Manchester was the most productive organization. Professor Ruth F. Itzhaki was the most influential researcher. The Journal of Alzheimer's Disease had published the most articles. Research on the mechanisms by which HSV infection contributes to AD remains a hotspot in the field, and future studies may further focus on antiviral therapeutic strategies targeting HSV-1 infection.

Conclusion: Our analysis provides basic information about research in AD and HSV-1. The current research hotspots in this field mainly include the mechanism of AD caused by HSV-1, and antiviral drugs to treat or prevent AD.

Keywords: Alzheimer's disease, Herpes simplex virus type 1, bibliometric, visualized analysis, VOSviewer, CiteSpace

Introduction

Alzheimer's disease (AD) is a widespread form of cognitive impairment, according to the Alzheimer's Association, the number of AD patients worldwide is projected to reach approximately 14 million by 2060.¹ Since its discovery in 1906, AD has received extensive attention from researchers. However, its pathogenesis is complex, and the exact mechanism has yet to be fully elucidated. The main pathological features of AD involve the formation of amyloid plaques by beta-amyloid (A β) and the development of neurofibrillary tangles (NFTs) due to hyperphosphorylated Tau protein. In AD, impaired clearance leads to A β accumulation. A β oligomers disrupt synaptic plasticity, trigger neuroinflammation,^{2,3} and promote Tau hyperphosphorylation, forming NFTs.⁴ Ultimately, these processes result in synaptic loss, neuronal death, and cognitive decline. Tau protein hyperphosphorylation leads to the formation of NFTs, disrupting microtubule stability, synaptic function, and neuronal survival, ultimately resulting in cognitive decline.⁵⁻⁷ This process is one of the core mechanisms of AD pathology and, together with A β pathology, drives disease progression. In addition to the previously proposed amyloid hypothesis, it is also believed to be associated with genetic factors, lifestyle, environmental factors, and gut microbiota, among others.^{8,9} The apolipoprotein E ϵ 4 allele (APOE- ϵ 4) promotes disease progression by impairing A β clearance and exacerbating Tau pathology,^{10,11} while mutations in APP,

PSEN1, and PSEN2 increase A β production and deposition.¹² Additionally, environmental factors such as diet and physical activity significantly influence the onset and progression of AD by modulating oxidative stress (OS), inflammation, and A β accumulation.^{13,14} The exact cause of AD remains unknown. Emerging theories suggest that infections caused by bacteria, viruses, or parasites may play a role in AD pathogenesis.^{15–19}

Herpes simplex virus type 1 (HSV-1) is a double-stranded DNA virus belonging to the α -herpesvirus family, primarily transmitted through direct contact with infected saliva or herpetic fluid, and characterized by its ability to establish latent infections and undergo reactivation.²⁰ According to 2020 global estimates, the prevalence of HSV-1 infection among individuals aged 15–49 years was approximately 66.6% (3.7356 billion people).²¹ Primary HSV-1 infection typically occurs during childhood and may present as oral herpes or remain asymptomatic. Following primary infection, the virus establishes a lifelong latency in the sensory neurons of the trigeminal ganglion.²² Under certain conditions such as psychological stress, physical trauma, or immunosuppression, latent HSV-1 can be reactivated.²³ Emerging evidence suggests that recurrent HSV-1 infections in the central nervous system (CNS) and their cumulative neurotoxic effects may lead to progressive neuronal damage, resembling the pathological changes observed in AD.²⁴

Research has shown that HSV-1 can be detected in the brain tissues of both AD patients and normal elderly individuals, with a positive correlation between herpes virus load in the brain and the severity of dementia.^{25–27} Reactivation of HSV-1 can induce neuroinflammatory responses and OS, thereby promoting the production and deposition of A β .^{28,29} Notably, although HSV-1 infection is detectable in normal elderly populations, they do not exhibit clinical symptoms, which may be related to the absence of the AD risk gene APOE- ϵ 4.^{30,31} Carriers of the APOE- ϵ 4 allele are more susceptible to HSV-1 induced neuronal damage due to their impaired A β clearance capacity, which significantly increases their risk of developing AD. Further studies using human brain tissue models have confirmed that repetitive injury can lead to HSV-1 reactivation and induce the production of AD-related pathological phenotypes.³² This finding suggests that the APOE- ϵ 4 allele may contribute to the pathogenesis of AD by potentiating the neurotoxic effects of HSV-1 reactivation. In recent years, significant progress has been made in understanding the relationship between AD and HSV-1, resulting in a wealth of literature. However, there remains a paucity of systematic organization and quantitative analysis of research in this field. Conducting such studies will help comprehensively understand the current state of development, identify research hotspots, and provide important references for future research directions.

Bibliometrics as an interdisciplinary research methodology, employs mathematical and statistical approaches to quantitatively analyze knowledge carriers, thereby elucidating the relationships among disciplines, research fields, scientific publications, and authors.^{33,34} This methodology has been extensively applied in both domestic and international contexts, demonstrating its effectiveness in analyzing the current research status and predicting future development trends across various disciplines.³⁵ Among the most widely utilized visualization tools in bibliometric analysis are CiteSpace and VOSviewer, which have been extensively employed in scientific mapping and knowledge domain visualization.^{36–38}

In this study, we utilized VOSviewer v1.6.18, developed by the Centre for Science and Technology Studies at Leiden University in the Netherlands,³⁸ and CiteSpace R6.4.R1, developed by Professor Chao-Mei Chen,³⁹ to systematically analyze research on AD and HSV-1. Our objective is to elucidate the current knowledge structure and identify potential future research trajectories in this field.

Materials and Methods

Literature Data Sources and Inclusion

The Web of Science Core Collection (WoSCC), recognized as a premier digital repository for scientific literature, has gained widespread acceptance among researchers and is widely regarded as the most reliable database for conducting bibliometric analyses.^{40,41} On June 1, 2024, we gathered bibliographic data from the WoSCC database using the search string: TS= [“Alzheimer’s disease”] AND TS= [“HSV-1” OR “Herpes simplex virus type 1”] to select SCI-E documents published from 1990–01–01 to 2024–06–01, including original research articles and reviews, written in English. However, it should be noted that data retrieved from the database may contain certain limitations, particularly regarding thematic relevance and accuracy. To mitigate potential biases arising from data quality issues and ensure the validity of subsequent

analyses, we implemented a two-stage screening process: we utilized the advanced filtering functions of WoSCC for initial data purification, followed by manual removal of documents with insufficient thematic relevance. The retrieved documents' full records and cited references were saved as a "TXT" file, suitable for VOSviewer and CiteSpace software.

Data Analysis and Visualization

Use "thesaurus_terms.txt" in VOSviewer to create thesaurus files to disambiguation, such as merged "AD" and "Alzheimer's disease", "HSV-1" and "Herpes simplex virus type 1", "amyloid beta" and "A β ", "apolipoprotein e4" and "APOE- ϵ 4", "wozniak, matthew a" and "wozniak, ma", "harvard med sch" and "harvard univ" in term analysis. The VOSviewer software is utilized to analyze information from articles regarding authors, source journals, institutions, countries, and cited literature. In the visual network graph, the color of an element indicates the cluster it belongs to. The size of a node represents the frequency of occurrence of a particular knowledge unit, and the strength of the links between nodes represents the relevance of the units. Use keyword bursts in CiteSpace software to study changes in research hot spots in the field. The burst detection analysis was conducted with a minimum duration of 1 year to identify statistically significant keyword bursts. The blue line denotes the time axis, while the red segment on the blue time axis indicates burst detection, showing the start year, end year, and burst duration.

Results

General Data

A total of 333 relevant publications focusing on the relationship between AD and HSV-1 were identified in the WoSCC database spanning the period from 1990 to 2024. Following the application of rigorous inclusion criteria, which restricted the search to peer-reviewed original research articles and review articles published in English while excluding irrelevant documents and noise words, 287 qualified publications were ultimately retrieved, comprising 215 original research articles and 72 comprehensive reviews. Statistical analysis revealed a significant upward trend in publication output over the study period, as illustrated in Figure 1.

Top Contributing Countries/ Regions

Publications were collected from 49 countries and regions. The United States was the most productive country, with 90 articles published, representing 31.36% of the total productivity. Subsequent leading contributors included England (53, 18.47%), Italy (40, 13.94%), China (31, 10.80%), and Spain (23, 8.01%), collectively representing a substantial portion of the global research output (Figure 2).




Figure 1 Trends of the number of published articles on HSV-1 and AD from 1990 to 2024.




Figure 2 The country/regions where the article was published and the number of publications on HSV-I and AD.

Top Productive Institutions

A total of 458 institutions have contributed to research on AD and HSV-1, with the University of Manchester emerging as the most productive institution (n=31), followed by the University of Autonoma Madrid. Furthermore, the University of Manchester demonstrated the highest citation impact, indicating the significant influence and recognition of its research contributions in this field (Figure 3).

Top Contributing and Co-Cited Journals

Between 1990 and 2024, 153 journals published articles about HSV-1 and AD. The Journal of Alzheimer’s Disease emerged as the most prolific publisher with 38 articles, followed by Neurobiology of Aging with 11 articles (Table 1). In the research field under investigation, the majority of articles are published in Q1 and Q2 journals. These journals in the Q1 and Q2 zones have demonstrated outstanding performance in many dimensions, such as the impact factor, citation frequency, and academic reputation. It can be seen that most articles in this field possess a high academic standard. Citation analysis identified the Journal of Virology as the most frequently cited source (n=986 citations), followed by the Journal of Alzheimer’s Disease (Table 2). Figure 4 presents the density visualization of the journal co-citation network,





Figure 3 The top 10 productive institutions on HSV-I and AD.

Rank	Journal	Document
1	Journal of alzheimer's disease	38
2	Neurobiology of aging	11
3	Frontiers in aging neuroscience	9
4	PLoS one	9
5	Alzheimers & dementia	8

Rank	Journal	Citations
1	The Journal of Virology	986
2	Journal of alzheimer's disease	913
3	PLoS one	438
4	Neurobiology of Aging	596
5	Proceedings of the National Academy of Sciences of the United States of America	544

Top Contributing and Co-Cited Authors

Figure 5b further presents the co-citation network of authors across a series of publications. Based on the information in






Figure 5 The co-occurrence map of authors on HSV-1 and AD. (a) Author production co-occurrence network in HSV-1 and AD-related fields. The nodes represent authors and the larger the size of the node, the more citations of authors. The links between nodes represent the co-cited relationship between authors. The thickness of links represents the frequency of the co-cited relationship between authors. (b) The density map of co-cited authors on HSV-1 and AD. The nodes represent authors and the higher the author's weight, the closer it is to red.

Table 3, which lists the top five authors by the number of publications, it can be concluded that Ruth Itzhaki is the most influential authority in this field. Her seminal research contributions have primarily focused on elucidating the etiological mechanisms and pathogenic processes underlying AD, with particular emphasis on its association with viral infections. Professor Itzhaki not only leads in publication output but also dominates citation metrics, highlighting her outstanding contributions and academic standing in this field.

Co-Citation Analysis of References

A total of 14007 references were cited in the field of HSV-1 and AD, Table 4 illustrates the top 10 most co-cited references. The most frequently co-cited article, “The risk of herpes simplex virus type 1 and Alzheimer’s disease in the brain”, was published in The Lancet (IF=98.4, Q1), one of the world’s most prestigious medical journals, underscoring its exceptional academic impact. The article concludes that the co-occurrence of HSV-1 cerebral infection and APOE-ε4 allele carriage constitutes a significant risk factor for AD development, providing crucial insights into the disease’s etiopathogenesis.

Table 3 The Top 5 Authors With the Highest Number of Published Articles

Rank	Author	Document	Affiliation
1	Ruth F. Itzhaki	32	University of Oxford/University of Manchester
2	Wozniak,MA	15	University of Manchester
3	Giovanni De Chiara	14	Sapienza University Rome
4	Palamara, Anna Teresa	13	Sapienza University Rome
5	Roberta Mancuso	13	Regis University/University of Milan

Table 4 The Top 10 Papers With the Highest Number of Citations

Rank	Title	First Author	Citations	Journal
1	Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease.	Ruth F. Itzhaki	153	The Lancet
2	Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques	Wozniak,MA	111	Journal of Pathology
3	Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation	Wozniak,MA	110	Neuroscience Letters

(Continued)

Table 4 (Continued).

Rank	Title	First Author	Citations	Journal
4	Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains	Gordon. Jamieson	98	Journal of Medical Virology
5	Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study	Letenneur I	83	PLoS one
6	Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1	Wozniak, MA	67	Journal of Alzheimer's Disease
7	Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients	Wozniak, MA	66	Journal of Medical Virology
8	Limbic Predilection in Alzheimer Dementia: Is Reactivated Herpesvirus Involved?	Ball MJ	65	Canadian Journal of Neurological Sciences
9	Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type.	Gordon, Jamieson	62	Journal of Pathology
10	Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus	Ben Readhead	61	Neuron

Analysis of Keywords

Keywords are a crucial component of academic papers, succinctly encapsulating the topic's essence and aiding the reader in comprehending the main content of the paper. Analyzing keywords can identify research hotspots,⁴² we use “keyword co-occurrence” in VOSviewer and “keyword burst” in CiteSpace to implement keyword clustering analysis and observe research hotspot changes. Then, 22 out of 1515 keywords with a frequency of 15 or more were extracted and analyzed by VOSviewer software. The top 10 most frequently used keywords included “herpes simplex virus type 1”, “Alzheimer's disease”, “brain”, “infection”, “amyloid”, “apoe”, “risk”, “central nervous system”, and “neurodegenerative disease”. The network visualization of keyword co-occurrence is shown in Figure 6a. The 22 core keywords were classified into four clusters. Cluster 1 (red color) focuses on how HSV-1 infection influences the accumulation of A β and tau proteins, thereby promoting the pathological progression of AD. Cluster 2 (green color) focuses on the epidemiological and biological associations between HSV-1 infection and AD. Cluster 3 (blue color) focuses on the interaction between the APOE gene and HSV-1 infection, as well as their combined impact on AD. Cluster 4 (yellow color) focuses on the infection of the central nervous system by HSV-1 and other pathogens, as well as their relationship with Mild Cognitive Impairment (MCI) and AD.

Figure 6b mainly shows the temporal trend of keyword co-occurrence, from the evolution of keywords, the research trajectory has shifted from direct links between HSV-1 infection and AD pathology (eg, NFTs, amyloid precursor protein(APP)) to broader mechanisms (eg, neuroinflammation, blood-brain barrier(BBB) dysfunction) and epidemiological connections (eg, infection, risk factors). The scope has expanded from HSV-1 alone to its interactions with other viruses and its role in neurodegenerative diseases. This reflects a deeper understanding of HSV-1-AD relationships, emphasizing multifactorial and multi-mechanistic interactions in disease pathogenesis. Future research hotspots are likely to focus on antiviral therapy, therapeutic targets, and multifactorial mechanisms of action.

Figure 6c illustrates the temporal evolution of research priorities in HSV-1 and AD. It highlights the top 25 most cited keywords. Among these, “mild cognitive impairment” was the most frequently mentioned keyword (n=9.32), followed by “risk” (n=6.86) and “polymerase chain reaction” (n=6.45). Presently, the commonly used keywords include “HSV-1”, “risk” and “cytomegalovirus infection”. Based on Figure 6c, we can speculate that the changes in research hotspots can be divided into three phases. The initial phase of research primarily focuses on utilizing PCR technology to detect the presence of viruses such as HSV-1 in brain tissue, exploring their potential association with neurological diseases. Preliminary studies suggest that HSV-1 infection may be linked to ND such as dementia (1991–2005). In the second phase, research has progressively delved into the molecular mechanisms, with a particular focus on how HSV-1 infection




Figure 6 The analysis of keywords in the field of HSV-1 and AD. (a) A network visualization map of co-occurring keywords. The color of an element indicates the cluster it belongs to. The larger the size of the node, the higher the frequency of the keyword. The links between keywords represent a co-occurrence relationship. (b) Time sequence chart of keyword clusters. The closer the color of the node is to yellow, the later the occurrence of keywords. (c) The top 25 keywords with the strongest citation bursts from 1983 to 2024. The blue line denotes the time axis, while the red segment on the blue time axis indicates burst detection, showing the start year, end year, and burst duration.

influences the pathophysiological processes associated with AD. Studies have encompassed the metabolism of APP, phosphorylation processes, the impact of the APOE- ϵ 4 gene, and dysfunction of the BBB. MCI, as a precursor stage to AD, has also garnered significant attention in these investigations (2005–2020). After 2020, the research focuses on HSV-1 infection as a risk factor for AD, particularly examining how it exacerbates the pathological progression of AD through mechanisms such as inducing OS and inflammatory responses. The relationship between the accumulation of A β and HSV-1 infection has also been a subject of interest. Furthermore, the potential links between other viral infections and AD have begun to be explored, broadening the scope of understanding in the field.

Discussion

AD is a widely recognized age-related ND,⁴³ characterized by typical pathological features including amyloid plaques formed by A β deposition and NFTs induced by hyperphosphorylation of microtubule-associated protein Tau.⁴⁴ Studies have shown that AD is a combination of genetic, lifestyle, and environmental factors,⁴⁵ but the exact cause has not yet been elucidated. HSV-1 is a widely prevalent virus with a global infection rate of 60%-90%, making it one of the most common viruses in humans.⁴⁶ This virus is characterized by latent infection and periodic reactivation, and its infection can lead to a variety of clinical manifestations, ranging from mild mucocutaneous lesions to severe neurological diseases.⁴⁷ In recent years, growing evidence suggests that HSV-1 infection may be an important environmental risk factor for AD. This study analyzed 287 articles on AD and HSV-1 in WoSCC. The VOSviewer software and CiteSpace software are utilized to investigate the knowledge structure, research hotspots, and emerging trends in this field through a comprehensive analysis of various aspects including countries, institutions, journals, authors, and keywords.

We conducted cluster analysis and temporal co-occurrence analysis on high-frequency keywords. Recent hot keywords include MCI, APOE- ϵ 4, OS, A β , tau protein, cytomegalovirus infection, and accumulation, among others. Through bibliometric analysis, we systematically organized the evolution of keywords in research related to AD and

HSV-1 infection. The analysis shows that research hotspots have shifted from early virus detection to molecular mechanisms and finally to the role of HSV-1 infection as a risk factor for AD. This evolution reflects the scientific community's deepening understanding of the relationship between HSV-1 and AD, from initial verification of viral presence to exploration of molecular mechanisms, and finally to comprehensive assessment of disease risk. This paper discusses some of the recent research hotspots in the field, providing researchers with additional directions for future studies.

HSV-1 infection promotes A β accumulation and tau phosphorylation, which are key pathological features of AD. Interestingly, A β is considered a natural antimicrobial peptide that can trap and neutralize pathogens by forming fibrillar structures, suggesting a protective role in the central nervous system.^{48,49} However, excessive A β accumulation due to high viral load may lead to plaque formation, neuroinflammation, and neuronal damage, ultimately contributing to AD pathogenesis. Studies show that HSV-1 disrupts the BBB to enter the CNS, triggering pathological changes.^{50–53} HSV-1 stimulates glial cells to produce cytokines, upregulates APP expression, induces A β generation,^{54,55} and impairs A β clearance by inhibiting autophagy and lysosomal function, promoting plaque formation.^{56–58} Additionally, HSV-1 triggers tau phosphorylation, leading to NFTs.⁵⁹ Phosphorylated tau spreads via extracellular vesicles (EVs), exacerbating neurodegeneration.^{60,61} These changes align with core AD features, supporting HSV-1's role in AD development. Repeated reactivation of HSV-1 may lead to excessive production of reactive oxygen species (ROS),⁶² thereby inducing OS.⁶³ ROS upregulate γ -secretase and BACE-1, increasing A β production and impairing its clearance.^{64–66} Simultaneously, protein oxidative damage caused by OS promotes tau self-aggregation, accelerating the formation of NFTs.^{67,68} Furthermore, the CNS is particularly vulnerable to OS,^{69,70} leading to impaired neuronal function and reduced survival rates, ultimately potentially contributing to AD.^{71,72}

The APOE- ϵ 4 gene is the most common genetic risk factor for AD. Studies have shown that individuals carrying the APOE- ϵ 4 genotype who are HSV-1 positive have a significantly higher risk of developing AD.³¹ Research by Javier S. Burgos revealed that during the latent phase of viral infection, APOE- ϵ 4 mice exhibited significantly higher viral loads in the brain compared to other genotypes.⁷³ This may be because APOE- ϵ 4 and HSV-1 share the same binding site (heparan sulfate proteoglycan),^{74,75} allowing HSV-1 to more easily enter neurons and promote its spread between neurons. By maintaining the balance of lipid metabolism and antioxidant capacity, APOE- ϵ 3 protects neurons from damage caused by HSV-1 infection, resulting in APOE- ϵ 3 carriers typically exhibiting milder disease symptoms and slower disease progression following HSV-1 infection.^{15,76} Besides, APOE- ϵ 2 reduces the inflammatory response after HSV-1 infection by enhancing the expression of anti-inflammatory cytokines while suppressing the release of pro-inflammatory cytokines.^{25,77} The antioxidant activity of APOE- ϵ 4 is lower than that of APOE- ϵ 3 and APOE- ϵ 2, making neurons of APOE- ϵ 4 carriers more vulnerable to damage during the OS triggered by HSV-1 infection.^{76,78} Jose L. Cantero further discovered that the association between HSV-1 infection and A β burden is regulated by the APOE- ϵ 4 genotype.⁷⁹ These findings highlight the broader impact of APOE genotypes on neurological and infectious diseases, underscoring the importance of further research into their roles in disease pathogenesis.

Co-infection with other viruses also increases the risk of AD. The co-infection of HSV-1 and varicella zoster virus or cytomegalovirus was found to be associated with a greater risk of AD in comparison to HSV-1 infection alone.^{80,81} The mechanism may be that the immune system is activated after viral infection, further reactivating latent HSV-1. Moreover, HSV-1 and SARS-CoV-2 co-infection may synergistically promote AD pathogenesis via mechanisms including autophagy dysregulation, OS exacerbation, and protein homeostasis disruption, thereby enhancing AD susceptibility.⁸²

Research has shown that the accumulation of HSV-1 infection is closely associated with an increased risk of AD. Some scholars have proposed that decreasing HSV-1 viral load may be an effective strategy for preventing AD in the future.^{83,84} For example, antiviral drugs could be used to inhibit HSV-1 replication or reactivation, thereby reducing viral damage to the nervous system.^{85–87} Alternatively, immune modulation could enhance the body's ability to clear HSV-1,⁸⁸ decreasing viral accumulation in the CNS. Antiviral drugs such as acyclovir for HSV infection can reduce the accumulation of A β and P-tau while reducing viral load.⁸⁷ Acyclovir has also been shown to prevent HSV-associated neuronal death.⁸⁹ Additionally, early intervention in HSV-1 infection, particularly during the MCI stage, may help delay or prevent the onset of AD.⁸⁵ The potential value of this strategy has been supported by preliminary studies. However, since HSV-1 performs viral transcription, DNA replication, capsid assembly, and DNA encapsulation in vivo, the

selection of intervention time points will be one of the directions of future research. Further large-scale clinical trials are needed to validate its efficacy and safety.

Research on HSV-1 infection and AD has evolved from initial pathological associations to broader areas, including genetics, viral infection characteristics, multi-virus comparisons, and comprehensive multi-mechanism studies. The research scope has continuously deepened, expanding from single-factor analyses to the interactions of multiple factors and mechanisms, gradually revealing the complex role of HSV-1 infection in AD and other ND. Currently, studies on the mechanisms by which HSV-1 infection contributes to AD remain a hotspot in the field. Future research is likely to focus more on antiviral strategies targeting HSV-1 infection, exploring their potential applications in the prevention and treatment of AD.

Limitations

The current mechanistic research landscape predominantly focuses on HSV-1-mediated AD pathogenesis through secondary pathways, particularly A β deposition and tau protein hyperphosphorylation, while direct mechanisms linking HSV-1 infection to AD neuropathology remain substantially underinvestigated. Furthermore, current therapeutic strategies remain predominantly confined to conventional antiviral agents and vaccine development, highlighting the critical need for innovative pharmacological approaches targeting novel molecular pathways in future research endeavors. Methodologically, the present study's scope is constrained by the limited sample size of included publications, necessitating future investigations to expand their analytical framework through comprehensive database integration and multilingual literature inclusion to enhance the generalizability and robustness of findings.

Conclusion

This comprehensive bibliometric analysis examined 287 original research articles focusing on the relationship between HSV-1 and AD, spanning from January 1990 to 2024 (June 1, 2024), retrieved from the WoSCC database. The collected data were systematically analyzed using VOSviewer and Citespace software to construct a detailed knowledge mapping framework. In recent years, there has been a rapid increase in the number of articles on HSV-1 and AD research. While there is currently substantial evidence that HSV-1 is involved in the pathogenesis of AD, the question remains controversial about whether this association is directly pathogenic or indirect, necessitating further mechanistic investigations to elucidate the underlying pathophysiological processes. Importantly, emerging evidence suggests that targeted anti-infective strategies and prophylactic vaccination approaches may represent promising therapeutic avenues for AD intervention, warranting further clinical investigation.

Data Sharing Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Ethics Approval

This is an observational study and does not involve ethics.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by “1+X” program for Clinical Competency Enhancement–Improvement of Clinical Technology Project, The Second Hospital of Dalian Medical University [2022LCJSGC04], “Xingliao Talent Plan”

Medical Master Project of Liaoning Province [YXMJ-QN-16], and Fundamental Scientific Research Project of Liaoning Provincial Department of Education[LJ212410161028].

Disclosure

The authors report no conflicts of interest in this work.

References

1. Alzheimer's disease. Alzheimer's disease facts and figures. *Alzheimers Dement*. 2024;20(5):3708–3821. doi:10.1002/alz.13809.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184–185. doi:10.1126/science.1566067
3. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016;8(6):595–608. doi:10.15252/emmm.201606210
4. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol*. 2013;12(2):207–216. doi:10.1016/s1474-4422(12)70291-0
5. Wang Y, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2016;17(1):5–21. doi:10.1038/nrn.2015.1
6. Ittner LM, Götz J. Amyloid- β and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65–72. doi:10.1038/nrn2967
7. Spire-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. *Neuron*. 2014;82(4):756–771. doi:10.1016/j.neuron.2014.05.004
8. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet*. 2024;404(10452):572–628. doi:10.1016/s0140-6736(24)01296-0
9. Zhou XP, Sun L-B, Liu W-H, et al. The complex relationship between gut microbiota and Alzheimer's disease: a systematic review. *Ageing Res Rev*. 2025;104:102637. doi:10.1016/j.arr.2024.102637
10. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. *Sci Transl Med*. 2011;3(89):89ra57. doi:10.1126/scitranslmed.3002156
11. Shi Y, Yamada K, Liddel SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*. 2017;549(7673):523–527. doi:10.1038/nature24016
12. Xiao X, Liu H, Liu X, et al. APP, PSEN1, and PSEN2 variants in Alzheimer's disease: systematic re-evaluation according to ACMG guidelines. *Front Aging Neurosci*. 2021;13:695808. doi:10.3389/fnagi.2021.695808
13. Scarmeas N, Stern Y, Tang M-X, et al. Mediterranean diet and risk for Alzheimer's disease. *Ann Neurol*. 2006;59(6):912–921. doi:10.1002/ana.20854
14. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *JAMA*. 2008;300(9):1027–1037. doi:10.1001/jama.300.9.1027
15. Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer's disease. *J Alzheimers Dis*. 2016;51(4):979–984. doi:10.3233/jad-160152
16. Piekut T, Hurla M, Banaszek N, et al. Infectious agents and Alzheimer's disease. *J Integr Neurosci*. 2022;21(2):73. doi:10.31083/j.jin2102073
17. Ganz T, Fainstein N, Ben-Hur T. When the infectious environment meets the AD brain. *Mol Neurodegener*. 2022;17(1):53. doi:10.1186/s13024-022-00559-3
18. Onisiforou A, Charalambous EG, Zanos P. Shattering the amyloid illusion: the microbial enigma of alzheimer's disease pathogenesis-from gut microbiota and viruses to brain biofilms. *Microorganisms*. 2025;13(1):90. doi:10.3390/microorganisms13010090
19. Onisiforou A, Spyrou GM. Immunomodulatory effects of microbiota-derived metabolites at the crossroad of neurodegenerative diseases and viral infection: network-based bioinformatics insights. *Front Immunol*. 2022;13:843128. doi:10.3389/fimmu.2022.843128
20. Cole S. Herpes simplex virus: epidemiology, diagnosis, and treatment. *Nurs Clin North Am*. 2020;55(3):337–345. doi:10.1016/j.cnur.2020.05.004
21. Harfouche M, AlMukdad S, Alareeki A, et al. Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses. *Sex Transm Infect*. 2024;sextrans-2024-056307. doi:10.1136/sextrans-2024-056307
22. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. *Clin Infect Dis*. 1998;26(3):541–555. doi:10.1086/514600
23. Gopinath D, Koe KH, Maharajan MK, et al. A comprehensive overview of epidemiology, pathogenesis and the management of herpes labialis. *Viruses*. 2023;15(1):225. doi:10.3390/v15010225
24. De Chiara G, Marcocci ME, Civitelli L, et al. APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. *PLoS One*. 2010;5(11):e13989. doi:10.1371/journal.pone.0013989
25. Chen F, Ke Q, Wei W, et al. Apolipoprotein E and viral infection: risks and mechanisms. *mol Ther Nucleic Acids*. 2023;33:529–542. doi:10.1016/j.omtn.2023.07.031
26. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. *J Pathol*. 2009;217(1):131–138. doi:10.1002/path.2449
27. Duarte LF, Farias MA, Álvarez DM, et al. Herpes simplex virus type 1 infection of the central nervous system: insights into proposed interrelationships with neurodegenerative disorders. *Front Cell Neurosci*. 2019;13:46. doi:10.3389/fncel.2019.00046
28. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. *Oxid Med Cell Longev*. 2015;2015:610813. doi:10.1155/2015/610813
29. Simpson DSA, Oliver PL. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. *Antioxidants (Basel)*. 2020;9(8). doi:10.3390/antiox9080743
30. Jamieson GA, Maitland NJ, Craske J, et al. Detection of herpes simplex virus type 1 DNA sequences in normal and Alzheimer's disease brain using polymerase chain reaction. *Biochem Soc Trans*. 1991;19(2):122s. doi:10.1042/bst019122s
31. Itzhaki RF, Lin W-R, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *Lancet*. 1997;349(9047):241–244. doi:10.1016/s0140-6736(96)10149-5
32. Cairns DM, Smiley BM, Smiley JA, et al. Repetitive injury induces phenotypes associated with Alzheimer's disease by reactivating HSV-1 in a human brain tissue model. *Sci Signal*. 2025;18(868):eado6430. doi:10.1126/scisignal.ado6430

33. Broadus RN. Toward a definition of “bibliometrics”. *Scientometrics*. 1987;12(5):373–379. doi:10.1007/BF02016680
34. Small HG. Visualizing science by citation mapping. *J Am Soc Inf Sci*. 1999;50(9):799–813. doi:10.1002/(SICI)1097-4571(1999)50:9<799::AID-ASI9>3.0.CO;2-G
35. Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. *J Informetrics*. 2017;11(4):959–975. doi:10.1016/j.joi.2017.08.007
36. Cobo MJ, López-Herrera AG, Herrera-Viedma E, et al. Science mapping software tools: review, analysis, and cooperative study among tools. *J Am Soc Inf Sci Technol*. 2011;62(7):1382–1402. doi:10.1002/asi.21525
37. Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. *Proc Natl Acad Sci*. 2004;101(suppl_1):5303–5310. doi:10.1073/pnas.0307513100
38. van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. *Scientometrics*. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
39. Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. *J Am Soc Inf Sci Technol*. 2006;57(3):359–377. doi:10.1002/asi.20317
40. Ding X, Yang Z. Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. *Electronic Commerce Res*. 2022;22(3):787–809. doi:10.1007/s10660-020-09410-7
41. Merigó JM, Yang J-B. A bibliometric analysis of operations research and management science. *Omega*. 2017;73:37–48. doi:10.1016/j.omega.2016.12.004
42. Li D, Yu D, Li Y, et al. A bibliometric analysis of PROTAC from 2001 to 2021. *Eur J Med Chem*. 2022;244:114838. doi:10.1016/j.ejmech.2022.114838
43. Lehrer S, R Feinstein PH. Vaccination reduces risk of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. *Discov Med*. 2022;34(172):97–101. doi:10.1038/s41588-021-00785-3
44. Zheng Q, Wang X. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy. *Protein Cell*. 2024. doi:10.1093/procel/pwae026
45. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413–446. doi:10.1016/s0140-6736(20)30367-6
46. Wijesinghe VN, Farouk IA, Zabidi NZ, et al. Current vaccine approaches and emerging strategies against herpes simplex virus (HSV). *Expert Rev Vaccines*. 2021;20(9):1077–1096. doi:10.1080/14760584.2021.1960162
47. Kaewpoowat Q, Salazar L, Aguilera E, et al. Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes. *Infection*. 2016;44(3):337–345. doi:10.1007/s15010-015-0867-6
48. Kumar DK, Choi SH, Washicosky KJ, et al. Amyloid- β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. *Sci Transl Med*. 2016;8(340):340ra72. doi:10.1126/scitranslmed.aaf1059
49. Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. *Alzheimers Dement*. 2018;14(12):1602–1614. doi:10.1016/j.jalz.2018.06.3040
50. Chagnot A, Barnes SR, Montagne A. Magnetic resonance imaging of blood-brain barrier permeability in dementia. *Neuroscience*. 2021;474:14–29. doi:10.1016/j.neuroscience.2021.08.003
51. van de Haar HJ, Burgmans S, Hofman PAM, et al. Blood-brain barrier impairment in dementia: current and future in vivo assessments. *Neurosci Biobehav Rev*. 2015;49:71–81. doi:10.1016/j.neubiorev.2014.11.022
52. Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. *CNS Drugs*. 2017;31(2):109–133. doi:10.1007/s40263-016-0405-9
53. Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune Encephalitis Misdiagnosis in Adults. *JAMA Neurol*. 2023;80(1):30–39. doi:10.1001/jamaneurol.2022.4251
54. Bourgade K, Dupuis G, Frost EH, et al. Anti-viral properties of amyloid- β Peptides. *J Alzheimers Dis*. 2016;54(3):859–878. doi:10.3233/jad-160517
55. Bourgade K, Garneau H, Giroux G, et al. β -Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. *Biogerontology*. 2015;16(1):85–98. doi:10.1007/s10522-014-9538-8
56. Wang Z, Liu J, Han J, et al. Herpes simplex virus 1 accelerates the progression of Alzheimer’s disease by modulating microglial phagocytosis and activating NLRP3 pathway. *J Neuroinflammation*. 2024;21(1):176. doi:10.1186/s12974-024-03166-9
57. Feng S, Liu Y, Zhou Y, et al. Mechanistic insights into the role of herpes simplex virus 1 in Alzheimer’s disease. *Front Aging Neurosci*. 2023;15:1245904. doi:10.3389/fnagi.2023.1245904
58. Ripa I, Andreu S, López-Guerrero JA, et al. Interplay between autophagy and herpes simplex virus type 1: ICP34.5, one of the main actors. *Int J mol Sci*. 2022;23(21):13643. doi:10.3390/ijms232113643
59. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. *J Alzheimers Dis*. 2009;16(2):341–350. doi:10.3233/jad-2009-0963
60. Protto V, Miteva MT, Iannuzzi F, et al. HSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles. *mBio*. 2024;15(10):e0152224. doi:10.1128/mbio.01522-24
61. Trunfio M, Di Girolamo L, Ponzetta L, et al. Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV. *J Neurovirol*. 2023;29(1):100–105. doi:10.1007/s13365-022-01105-z
62. Gonzalez-Dosal R, Horan KA, Rahbek SH, et al. HSV infection induces production of ROS, which potentiate signaling from pattern recognition receptors: role for S-glutathionylation of TRAF3 and 6. *PLoS Pathog*. 2011;7(9):e1002250. doi:10.1371/journal.ppat.1002250
63. Wongchitrat P, Chanmee T, Govitrapong P. Molecular mechanisms associated with neurodegeneration of neurotropic viral infection. *mol Neurobiol*. 2024;61(5):2881–2903. doi:10.1007/s12035-023-03761-6
64. Jo DG, Arumugam TV, Woo H-N, et al. Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer’s disease. *Neurobiol Aging*. 2010;31(6):917–925. doi:10.1016/j.neurobiolaging.2008.07.003
65. Ivaldo C, Passalacqua M, Furfaro AL, et al. Oxidative stress-induced MMP- and γ -secretase-dependent VE-cadherin processing is modulated by the proteasome and BMP9/10. *Sci Rep*. 2023;13(1):597. doi:10.1038/s41598-022-27308-2

66. Zhao M, Ma G, Yan X, et al. Microbial infection promotes amyloid pathology in a mouse model of Alzheimer's disease via modulating γ -secretase. *mol Psychiatry*. 2024;29(5):1491–1500. doi:10.1038/s41380-024-02428-5
67. Tahir M, Kang MH, Park TJ, et al. Multifaceted neuroprotective approach of trolox in Alzheimer's disease mouse model: targeting A β pathology, neuroinflammation, oxidative stress, and synaptic dysfunction. *Front Cell Neurosci*. 2024;18:1453038. doi:10.3389/fncel.2024.1453038
68. Sharma C, Kim SR. Linking oxidative stress and proteinopathy in Alzheimer's disease. *Antioxidants (Basel)*. 2021;10(8). doi:10.3390/antiox10081231
69. Sienes Bailo P, Llorente Martín E, Calmarza P, et al. The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies. *Adv Lab Med*. 2022;3(4):342–360. doi:10.1515/almed-2022-0111
70. Singh M, Kapoor A, Bhatnagar A. Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls. *Chem Biol Interact*. 2015;234:261–273. doi:10.1016/j.cbi.2014.12.028
71. Houldsworth A. Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants. *Brain Commun*. 2024;6(1):fcad356. doi:10.1093/braincomms/fcad356
72. Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. *Cell Death Differ*. 2021;28(7):2029–2044. doi:10.1038/s41418-021-00814-y
73. Burgos JS, Ramirez C, Sastre I, et al. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. *J Virol*. 2006;80(11):5383–5387. doi:10.1128/jvi.00006-06
74. Dobson CB, Sales S, Hoggard P, et al. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. *J Infect Dis*. 2006;193(3):442–450. doi:10.1086/499280
75. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disorders. *Prog Lipid Res*. 2006;45(1):73–90. doi:10.1016/j.plipres.2005.11.003
76. Butterfield DA, Mattson MP. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. *Neurobiol Dis*. 2020;138:104795. doi:10.1016/j.nbd.2020.104795
77. Miller RM, Federoff HJ. Isoform-specific effects of ApoE on HSV immediate early gene expression and establishment of latency. *Neurobiol Aging*. 2008;29(1):71–77. doi:10.1016/j.neurobiolaging.2006.09.006
78. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. *Nat Genet*. 1996;14(1):55–61. doi:10.1038/ng0996-55
79. Cantero JL, Atienza M, Sastre I, et al. Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging. *Alzheimers Res Ther*. 2024;16(1):68. doi:10.1186/s13195-024-01437-4
80. Shin E, Chi SA, Chung T-Y, et al. The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study. *Alzheimers Res Ther*. 2024;16(1):57. doi:10.1186/s13195-024-01418-7
81. Lövhim H, Olsson J, Weidung B, et al. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer's disease development. *J Alzheimers Dis*. 2018;61(3):939–945. doi:10.3233/jad-161305
82. Onisiforou A, Zanos P. From viral infections to Alzheimer's disease: unveiling the mechanistic links through systems bioinformatics. *J Infect Dis*. 2024;230(Supplement_2):S128–s140. doi:10.1093/infdis/jiae242
83. Wozniak MA, Itzhaki RF. Antiviral agents in Alzheimer's disease: hope for the future? *Ther Adv Neurol Disord*. 2010;3(3):141–152. doi:10.1177/1756285610370069
84. Tejeda M, Farrell J, Zhu C, et al. DNA from multiple viral species is associated with Alzheimer's disease risk. *Alzheimers Dement*. 2024;20(1):253–265. doi:10.1002/alz.13414
85. Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer's Disease. *Front Aging Neurosci*. 2018;10:324. doi:10.3389/fnagi.2018.00324
86. Devanand DP. Viral hypothesis and antiviral treatment in Alzheimer's disease. *Curr Neurol Neurosci Rep*. 2018;18(9):55. doi:10.1007/s11910-018-0863-1
87. Wozniak MA, Frost AL, Preston CM, et al. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. *PLoS One*. 2011;6(10):e25152. doi:10.1371/journal.pone.0025152
88. Awasthi S, Friedman HM. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes. *J Infect Dis*. 2014;209(6):813–815. doi:10.1093/infdis/jit658
89. Prasad KM, Eack SM, Keshavan MS, et al. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. *Schizophr Bull*. 2013;39(4):857–866. doi:10.1093/schbul/sbs040